BD to Offer Drug Candidate ADME Screening with BioTrove System | GenomeWeb
NEW YORK (GenomeWeb News) – BioTrove said today that Becton Dickinson will offer BioTrove’s mass spectrometry-based screening and analysis system as part of its ADME analysis services for pharmaceutical and biotech companies
 
Under the agreement, BD will offer BioTrove’s mass spec-based RapidFire Technology as part of its drug absorption, distribution, metabolism, and elimination services offering.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.